Provider and household costs of Plasmodium vivax malaria episodes: A multicountry comparative analysis of primary trial data

Angela Devine, Ayodhia P. Pasaribu, Tedlla Teferi, Huong Thu Pham, Ghulam Rahim Awab, Febrina Contantia, Thuy Nhien Nguyen, Viet Thanh Ngo, Tinh Hien Tran, Asrat Hailu, Kim Gilchrist, Justin A. Green, Gavin Ckw Koh, Kamala Thriemer, Walter Rj Taylor, Nicholas Pj Day, Ric N. Price, Yoel Lubell

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
65 Downloads (Pure)


Objective: To determine household and health-care provider costs associated with Plasmodium vivax infection across a range of endemic settings.

Methods: We collected cost data alongside three multicentre clinical trials of P. vivax treatment in Afghanistan, Brazil, Colombia, Ethiopia, Indonesia, Philippines, Peru, Thailand and Viet Nam conducted between April 2014 to December 2017. We derived household costs from trial participant surveys administered at enrolment and again 2 weeks later to determine the costs of treatment and transportation, and the number of days that patients and their household caregivers were unable to undertake their usual activities. We determined costs of routine care by health-care providers by micro-costing the resources used to diagnose and treat P. vivax at the study sites.

Findings: The mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6–6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).

Conclusion: An episode of P. vivax malaria results in high costs to households. The costs of diagnosing and treating P. vivax are important inputs for future cost–effectiveness analyses to ensure optimal allocation of resources for malaria elimination.

Original languageEnglish
Pages (from-to)828-836
Number of pages9
JournalBulletin of the World Health Organization
Issue number12
Publication statusPublished - 1 Dec 2019


Dive into the research topics of 'Provider and household costs of Plasmodium vivax malaria episodes: A multicountry comparative analysis of primary trial data'. Together they form a unique fingerprint.

Cite this